EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases.

María C Cano-Salas iD, José L Miguel-Reyes iD, Erika C López-Estrada, Jorge Salas-Hernández, Monserrat E Arroyo-Rojas, Mauricio Castañeda-Valdivia, Monserrat Escobar-Preciado, Homero Garcés-Flores, Silvia Guzmán-Vázquez, Sergio R García-García, Herman Soto-Molina

Revista Alergia México · 2024

DOI: 10.29262/ram.v71i4.1295 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Revista Alergia México, 2024. Verfasst von María C Cano-Salas und 10 weiteren Autor:innen. Beteiligte Einrichtung: PhD, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. carmencano09@gmail.com. Hauptthemen laut MEDLINE: Asthma, Cost-Benefit Analysis. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective: to perform a cost-effectiveness analysis of asthma treatment with budesonide/formoterol against other treatment options used at Mexico’s National Institute for Respiratory Diseases.

Methods

A complete economic evaluation of cost-effectiveness from a public health perspective, comparing the use of budesonide/formoterol as maintenance therapy with fluticasone/vilanterol in 103 female asthma patients managed at INER between 2015 and 2021.

Results

Average cost per patient was $743.23 USD, $733.36 USD for budesonide/formoterol and $767.24 USD for fluticasone/vilanterol. Pharmacological treatment represented over 70% of management costs for both groups, followed by follow-up visits and exacerbation management costs. LABA-ICS represented the highest proportion of pharmacologic management costs with a statistically significant difference amongst groups with an incremental cost of $80.17 USD for the fluticasone/vilanterol group. The budesonide/formoterol group showed an ICER of $613.31 USD for reducing the proportion of patients experiencing exacerbations during follow-up. Considering the willingness to pay threshold based on one GDP per capita ($10,902.98 USD in 2022), budesonide/formoterol represented a very cost-effective option.

Conclusions

The ICER favored budesonide/formoterol over fluticasone/vilanterol in terms of cost-effectiveness. A 5.5% reduction in patient exacerbations indicated decreased disease burden. While not statistically significant, fewer exacerbations per patient might still cut costs by lowering emergency visits and hospitalizations. Keywords: Cost-effectiveness analysis; Asthma; Budesonide; Formoterol fumarate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaCost-Benefit AnalysisHumansFemaleAdultMiddle AgedBudesonide, Formoterol Fumarate Drug CombinationFormoterol FumarateBudesonideFluticasoneAnti-Asthmatic AgentsDrug CombinationsBenzyl AlcoholsChlorobenzenesMaintenance ChemotherapyYoung AdultBronchodilator AgentsMexicoAdolescent

Stichwörter der Autor:innen

AsthmaBudesonideCost-effectiveness analysisFormoterol fumarate

Substanzen

Budesonide, Formoterol Fumarate Drug CombinationFormoterol FumarateBudesonideFluticasoneAnti-Asthmatic AgentsDrug CombinationsBenzyl AlcoholsChlorobenzenesvilanterolBronchodilator Agents

Autor:innen und Institutionen

  • PhD, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico. carmencano09@gmail.com.
  • PhD, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico.
  • Bachelor in Basic Biomedical Research, HS Pharmacoeconomic Research, Mexico City, Mexico.
  • PhD, HS Pharmacoeconomic Research, Mexico City, Mexico.
  • Pharmaceutical chemistry s, HS Pharmacoeconomic Research, Mexico City, Mexico.
  • Master's in economics, HS Pharmacoeconomic Research, Mexico City, Mexico.

ORCID-Profile: María C Cano-Salas, José L Miguel-Reyes

Zitieren

APA

Cano-Salas, M. C., Miguel-Reyes, J. L., López-Estrada, E. C., Salas-Hernández, J., Arroyo-Rojas, M. E., Castañeda-Valdivia, M., Escobar-Preciado, M., Garcés-Flores, H., Guzmán-Vázquez, S., García-García, S. R., & Soto-Molina, H. (2024). Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. Revista Alergia México. https://doi.org/10.29262/ram.v71i4.1295

Vancouver

Cano-Salas MC, Miguel-Reyes JL, López-Estrada EC, Salas-Hernández J, Arroyo-Rojas ME, Castañeda-Valdivia M, et al. Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. Revista Alergia México. 2024. doi:10.29262/ram.v71i4.1295

BibTeX
@article{CanoSalas2024,
  author = {Cano-Salas, María C and Miguel-Reyes, José L and López-Estrada, Erika C and Salas-Hernández, Jorge and Arroyo-Rojas, Monserrat E and Castañeda-Valdivia, Mauricio and Escobar-Preciado, Monserrat and Garcés-Flores, Homero and Guzmán-Vázquez, Silvia and García-García, Sergio R and Soto-Molina, Herman},
  title = {Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases},
  journal = {Revista Alergia México},
  year = {2024},
  doi = {10.29262/ram.v71i4.1295}
}
Kostenlos starten →